ArticleAmerican heart journal plus : cardiology research and practice2025
Prevalence and mortality rate of heart failure across demographic groups in the United States: 2001-2020.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a serious, difficult-to-diagnose condition. Tracking its evolving burden using survey data is key to developing strategies to reduce its impact. Methods: We use NHANES and CDC-WONDER to determine prevalence and death rates in the U.S. population between 2001 and 2020 across age, sex, and race/ethnicity. We also estimated a crude mortality-to-prevalence ratio (proxy CFR)as a descriptive measure of lethality across demographic groups. Results: Age-adjusted HF prevalence rates for both males and females increased from 2001 to 2020, with males consistently having higher rates. By 2020, the age-adjusted mortality rate was 32.08 per 100,000 males and 25.69 per 100,000 females. HF prevalence increased across all racial groups (from 1.73 % to 1.92 %, 2.47 % to 2.8 %, and 3.68 % to 4.14 % for Hispanic, White, and Black, respectively). Non-Hispanic Blacks showed a steeper rise in both crude and age-adjusted mortality rates from 2001 to 2020, while the proxy CFR for non-Hispanic Whites remained highest among all groups both in 2001 (23.95/2.47 = 9.70) and in 2020 (29.29/2.80 = 10.46). Conclusions: We observe rising trends in both prevalence and mortality across all groups. While the absolute burden is highest in Whites, the increase in HF rates among Blacks and the higher mortality rates in males highlight the need for targeted interventions. The findings underscore the importance of continued surveillance and considering multiple metrics (absolute numbers, rates within groups, and proxy CFR) to address HF's burden in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.